Your browser doesn't support javascript.
loading
Effect of familial clustering in the genetic screening of 235 French ALS families.
Corcia, Philippe; Camu, William; Brulard, Celine; Marouillat, Sylviane; Couratier, Philippe; Camdessanché, Jean-Philippe; Cintas, Pascal; Verschueren, Annie; Soriani, Marie-Helene; Desnuelle, Claude; Fleury, Marie-Céline; Guy, Nathalie; Cassereau, Julien; Viader, Fausto; Pittion-Vouyovitch, Sophie; Danel, Veronique; Kolev, Ivan; Le Masson, Gwendal; Beltran, Stephane; Salachas, Francois; Bernard, Emilien; Pradat, Pierre-François; Blasco, Hélène; Lanznaster, Débora; Hergesheimer, Rudolph; Laumonnier, Frederic; Andres, Christian R; Meininger, Vincent; Vourc'h, Patrick.
Afiliação
  • Corcia P; ALS Centre, Department of Neurology, CHU Tours, Tours, Centre, France corcia@med.univ-tours.fr.
  • Camu W; UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.
  • Brulard C; Montpellier 2 University, Montpellier, Languedoc-Roussillon, France.
  • Marouillat S; UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.
  • Couratier P; UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.
  • Camdessanché JP; ALS Center, Departement of neurology, CHU Limoges, Limoges, Limousin, France.
  • Cintas P; UMR-S 1094 NET, Limoges, France.
  • Verschueren A; Neurology, Saint-Etienne University Hospital Bellevue Site, Saint-Etienne, Rhône-Alpes, France.
  • Soriani MH; Neurology, CHU Toulouse, Toulouse, Midi-Pyrénées, France.
  • Desnuelle C; Centre de référence des maladies neuromusculaires et de la SLA, Marseille Public University Hospital System, Marseille, Provence-Alpes-Côte d'Azu, France.
  • Fleury MC; CHU Nice, Nice, Provence-Alpes-Côte d'Azu, France.
  • Guy N; Centre de reference des maladies neuromusculaires SLA, Neurosciences department, CHU Nice, Nice, Provence-Alpes-Côte d'Azu, France.
  • Cassereau J; Neurology, CHU Strasbourg, Strasbourg, Alsace, France.
  • Viader F; CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Pittion-Vouyovitch S; Neurology, CHU Angers, Angers, Pays de la Loire, France.
  • Danel V; U1077, INSERM, Paris, Caen, France.
  • Kolev I; Neurology, Hopital Central, Nancy, France.
  • Le Masson G; Medical Pharmacology, Lille University Hospital Center, Lille, Hauts-de-France, France.
  • Beltran S; Hospital Centre Saint Brieuc, Saint Brieuc, Bretagne, France.
  • Salachas F; Neurology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, Aquitaine, France.
  • Bernard E; ALS Center, Francois-Rabelais University, Tours, Centre-Val de Loire, France.
  • Pradat PF; ALS Center, Neurology, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France.
  • Blasco H; University Hospital Centre Lyon, Lyon, Auvergne-Rhône-Alpes, France.
  • Lanznaster D; Fédération de Neurologie, Centre Référent SLA, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France.
  • Hergesheimer R; CNRS, INSERM, Laboratoire d'Imagerie Biomédicale (LIB), Université Pierre et Marie Curie Faculté de Médecine, Paris, Île-de-France, France.
  • Laumonnier F; Biochemistry and Molecular Biology Department, Université Francois-Rabelais de Tours, Tours, Centre-Val de Loire, France.
  • Andres CR; Neurogenetics and Neurometabolomics, Imagerie et cerveau, Tours, France.
  • Meininger V; UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.
  • Vourc'h P; UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.
J Neurol Neurosurg Psychiatry ; 92(5): 479-484, 2021 05.
Article em En | MEDLINE | ID: mdl-33408239
ABSTRACT

OBJECTIVES:

To determine whether the familial clustering of amyotrophic lateral sclerosis (ALS) cases and the phenotype of the disease may help identify the pathogenic genes involved.

METHODS:

We conducted a targeted next-generation sequencing analysis on 235 French familial ALS (FALS), unrelated probands to identify mutations in 30 genes linked to the disease. The genealogy, that is, number of cases and generations with ALS, gender, age, site of onset and the duration of the disease were analysed.

RESULTS:

Regarding the number of generations, 49 pedigrees had only one affected generation, 152 had two affected generations and 34 had at least three affected generations. Among the 149 pedigrees (63.4%) for which a deleterious variant was found, an abnormal G4C2 expansion in C9orf72 was found in 98 cases as well as SOD1, TARBP or FUS mutations in 30, 9 and 7 cases, respectively. Considering pedigrees from the number of generations, abnormal G4C2 expansion in C9orf72 was more frequent in pedigrees with pairs of affected ALS cases, which represented 65.2% of our cohort. SOD1 mutation involved all types of pedigrees. No TARDBP nor FUS mutation was present in monogenerational pedigrees. TARDBP mutation predominated in bigenerational pedigrees with at least three cases and FUS mutation in multigenerational pedigrees with more than seven cases, on average, and with an age of onset younger than 45 years.

CONCLUSION:

Our results suggest that familial clustering, phenotypes and genotypes are interconnected in FALS, and thus it might be possible to target the genetic screening from the familial architecture and the phenotype of ALS cases.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína C9orf72 / Esclerose Lateral Amiotrófica / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína C9orf72 / Esclerose Lateral Amiotrófica / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article